Neuphoria Therapeutics
NEUP · NASDAQ
$3.39+$0.08 (+2.42%)TodayMarket closed ·
Prev close $3.31
Key indicators
NEUP profitability and balance sheet ratios
EPS -$0.907 in Jun 2026, against -$4.67 a year earlier.
| Period | EPS |
|---|---|
| Sep 2024 | -$0.0034 |
| Dec 2024 | -$1.23 |
| Mar 2025 | $6.55 |
| Jun 2025 | -$4.67 |
| Sep 2025 | -$4.41 |
| Dec 2025 | $0.4109 |
| Mar 2026 | -$0.0933 |
| Jun 2026 | -$0.907 |
Income statement
No financial statements are reported for Neuphoria Therapeutics.
Balance sheet
What the company owns and owes at period end
Total assets
Total liabilities
| Line item | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Total assets | $36.6M | $34.8M | $28.7M |
| Total liabilities | $6.9M | $5.4M | $4.1M |
| Shareholder equity | $29.7M | $29.4M | $24.6M |
| Cash and short-term investments | $22.2M | $19.4M | $19.9M |
| Total debt | $0.0M | $0.0M | $0.0M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.